These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. Schneider D; Bianchini G; Horgan D; Michiels S; Witjes W; Hills R; Plun-Favreau J; Brand A; Lawler M; Public Health Genomics; 2015; 18(6):349-58. PubMed ID: 26571110 [TBL] [Abstract][Full Text] [Related]
29. The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer. Wei CC; Nie FQ; Jiang LL; Chen QN; Chen ZY; Chen X; Pan X; Liu ZL; Lu BB; Wang ZX Oncotarget; 2017 Jan; 8(3):5233-5246. PubMed ID: 28029651 [TBL] [Abstract][Full Text] [Related]
30. Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers. Jiang T; Xu X; Qiao M; Li X; Zhao C; Zhou F; Gao G; Wu F; Chen X; Su C; Ren S; Zhai C; Zhou C BMC Cancer; 2018 Mar; 18(1):267. PubMed ID: 29514610 [TBL] [Abstract][Full Text] [Related]
32. Pseudogenes transcribed in breast invasive carcinoma show subtype-specific expression and ceRNA potential. Welch JD; Baran-Gale J; Perou CM; Sethupathy P; Prins JF BMC Genomics; 2015 Feb; 16(1):113. PubMed ID: 25765044 [TBL] [Abstract][Full Text] [Related]
33. Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review. Bibault JE; Fumagalli I; Ferté C; Chargari C; Soria JC; Deutsch E Cancer Metastasis Rev; 2013 Dec; 32(3-4):479-92. PubMed ID: 23595306 [TBL] [Abstract][Full Text] [Related]
34. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Lan H; Lu H; Wang X; Jin H Biomed Res Int; 2015; 2015():125094. PubMed ID: 25874201 [TBL] [Abstract][Full Text] [Related]
35. A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data. Li Y; Kang K; Krahn JM; Croutwater N; Lee K; Umbach DM; Li L BMC Genomics; 2017 Jul; 18(1):508. PubMed ID: 28673244 [TBL] [Abstract][Full Text] [Related]
37. Mass Spectrometry Imaging for the Investigation of Intratumor Heterogeneity. Balluff B; Hanselmann M; Heeren RM Adv Cancer Res; 2017; 134():201-230. PubMed ID: 28110651 [TBL] [Abstract][Full Text] [Related]
38. [MUC4 research progress in tumor molecular markers]. Zhu H; You J Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2014 Feb; 31(1):233-6. PubMed ID: 24804517 [TBL] [Abstract][Full Text] [Related]
39. Sequence and transcriptional study of HNRPK pseudogenes, and expression and molecular modeling analysis of hnRNP K isoforms. Leopoldino AM; Carregaro F; Silva CH; Feitosa O; Mancini UM; Freitas JM; Tajara EH Genome; 2007 May; 50(5):451-62. PubMed ID: 17612614 [TBL] [Abstract][Full Text] [Related]
40. Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm. Martinez-Ledesma E; Verhaak RG; Treviño V Sci Rep; 2015 Jul; 5():11966. PubMed ID: 26202601 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]